David Toft
Research Subjects
David Toft has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Chadli
Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First St. Southwest, Rochester, MN 55905, USA
2 shared publicationsSara J. Felts
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota,1 Division of Endocrinology, Department of Medicine, University of Colorado Health Science Center, Denver, Colorado2
2 shared publicationsWilliam P. Sullivan
Department of Biochemistry and Molecular Biology, Mayo Graduate School, Rochester, MN 55905, USA
2 shared publicationsWilliam Sullivan
2 shared publicationsBridget Stensgard
Mayo Clinic, Department of Biochemistry and Molecular Biology, 200 First Street SW, Rochester, MN 55905; and †Centre National de la Recherche Scientifique-Unité Propre de Recherche 1524, Department of Endocrinology, 24 rue de Faubourg St. Jacques, 75014 Paris, France
1 shared publicationCem Elbi
Laboratory of Receptor Biology and Gene Expression, Building 41, Room B602, National Cancer Institute, Bethesda, MD 20892-5055, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2008
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 13 (1) , 117-118
Partners in surveillance and quality control
- 1 March 2008
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 13 (1) , 117-118
Open AccessPartners in surveillance and quality control
- Open Access
- 1 September 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (36) , 26235-26244
Defining the Requirements for Hsp40 and Hsp70 in the Hsp90 Chaperone Pathway
- 1 September 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (36) , 26235-26244
Open AccessDefining the Requirements for Hsp40 and Hsp70 in the Hsp90 Chaperone Pathway
- 1 March 2006
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (5) , 1722-1730
GCUNC-45 Is a Novel Regulator for the Progesterone Receptor/hsp90 Chaperoning Pathway
The hsp90 chaperoning pathway is a multiprotein system that is required for the production or activation of many cell regulatory proteins, including the progesterone receptor (PR). We report here the identity of GCUNC-45 as a novel modulator of PR chaperoning by hsp90. GCUNC-45, previously implicated in the activities of myosins, can interact in vivo and in vitro with both PR-A and PR-B and with hsp90. Overexpression and knockdown experiments show GCUNC-45 to be a positive factor in promoting PR function in the cell. GCUNC-45 binds to the ATP-binding domain of hsp90 to prevent the activation of its ATPase activity by the cochaperone Aha1. This effect limits PR chaperoning by hsp90, but this can be reversed by FKBP52, a cochaperone that is thought to act later in the pathway. These findings reveal a new cochaperone binding site near the N terminus of hsp90, add insight on the role of FKBP52, and identify GCUNC-45 as a novel regulator of the PR signaling pathway.
- 1 March 2006
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (5) , 1722-1730
GCUNC-45 Is a Novel Regulator for the Progesterone Receptor/hsp90 Chaperoning Pathway
The hsp90 chaperoning pathway is a multiprotein system that is required for the production or activation of many cell regulatory proteins, including the progesterone receptor (PR). We report here the identity of GCUNC-45 as a novel modulator of PR chaperoning by hsp90. GCUNC-45, previously implicated in the activities of myosins, can interact in vivo and in vitro with both PR-A and PR-B and with hsp90. Overexpression and knockdown experiments show GCUNC-45 to be a positive factor in promoting PR function in the cell. GCUNC-45 binds to the ATP-binding domain of hsp90 to prevent the activation of its ATPase activity by the cochaperone Aha1. This effect limits PR chaperoning by hsp90, but this can be reversed by FKBP52, a cochaperone that is thought to act later in the pathway. These findings reveal a new cochaperone binding site near the N terminus of hsp90, add insight on the role of FKBP52, and identify GCUNC-45 as a novel regulator of the PR signaling pathway.
- 1 December 2004
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 11 (12) , 1152-1155
Hsp90: from structure to phenotype
- 1 December 2004
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 11 (12) , 1152-1155
Hsp90: from structure to phenotype
- 22 June 2004
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2004 (238) , pl10
A Novel In Situ Assay for the Identification and Characterization of Soluble Nuclear Mobility Factors
The development of green fluorescent protein (GFP) technology combined with live cell microscopy techniques have revealed the dynamic properties of GFP-tagged proteins in the nucleus. The mobility of a GFP-tagged protein can be assessed using a quantitative photobleaching technique, fluorescence recovery after photobleaching (FRAP) analysis. FRAP experiments demonstrate that many nuclear proteins are highly mobile within the nucleus. However, the factors within the nucleus that regulate this mobility are not known. This is partly due to an absence of protocols that can be used to identify such nuclear mobility factors. We developed a novel in situ assay that combines a biochemical permeabilization and extraction procedure with a quantitative FRAP technique, a method we used to uncover a new functional role for molecular chaperones in the nuclear mobility of steroid receptors. This assay can readily be adapted to identify and characterize other nuclear mobility factors.
- 22 June 2004
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2004 (238) , pl10
A Novel In Situ Assay for the Identification and Characterization of Soluble Nuclear Mobility Factors
The development of green fluorescent protein (GFP) technology combined with live cell microscopy techniques have revealed the dynamic properties of GFP-tagged proteins in the nucleus. The mobility of a GFP-tagged protein can be assessed using a quantitative photobleaching technique, fluorescence recovery after photobleaching (FRAP) analysis. FRAP experiments demonstrate that many nuclear proteins are highly mobile within the nucleus. However, the factors within the nucleus that regulate this mobility are not known. This is partly due to an absence of protocols that can be used to identify such nuclear mobility factors. We developed a novel in situ assay that combines a biochemical permeabilization and extraction procedure with a quantitative FRAP technique, a method we used to uncover a new functional role for molecular chaperones in the nuclear mobility of steroid receptors. This assay can readily be adapted to identify and characterize other nuclear mobility factors.
- 1 September 2003
- Published by Rockefeller University Press
- Vol. 13 (9) , 555-64
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.
Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs such as 6-mercaptopurine. A common genetic polymorphism for TPMT is associated with large individual variations in thiopurine drug toxicity and therapeutic efficacy. TPMT*3A, the most common variant allele in Caucasians, has two alterations in amino acid sequence, resulting in striking decreases in TPMT protein levels. This phenomenon results, in part, from rapid degradation through a ubiquitin-proteasome-mediated process. We set out to test the hypothesis that chaperone proteins might be involved in targeting TPMT for degradation. As a first step, hsp90, hsp70 and the cochaperone hop were immunoprecipitated from a rabbit reticulocyte lysate (RRL) that included radioactively labelled *3A and wild-type TPMT. TPMT*3A was much more highly associated with all three chaperones than was the wild-type enzyme. The RRL was also used to confirm the accelerated degradation of *3A compared to wild-type TPMT. Treatment of RRL with the hsp90 inhibitor geldanamycin resulted in enhanced association of hsp90 with wild-type TPMT, an observation that correlated with accelerated ubiquitin-dependent degradation of wild-type TPMT. Geldanamycin treatment of COS-1 cells transfected with FLAG-tagged wild-type also resulted in a time and geldanamycin concentration-dependent decrease in TPMT activity and protein, which was compatible with results obtained in the RRL. These observations indicate that TPMT is a client protein for hsp90 and suggest that chaperone proteins, especially hsp90, are involved in targeting both TPMT*3A and, in the presence of geldanamycin, the wild-type allozyme for degradation. Therefore, chaperone proteins play an important mechanistic role in this clinically significant example of pharmacogenetic variation in drug metabolism.
- 1 September 2003
- Published by Rockefeller University Press
- Vol. 13 (9) , 555-64
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.
Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs such as 6-mercaptopurine. A common genetic polymorphism for TPMT is associated with large individual variations in thiopurine drug toxicity and therapeutic efficacy. TPMT*3A, the most common variant allele in Caucasians, has two alterations in amino acid sequence, resulting in striking decreases in TPMT protein levels. This phenomenon results, in part, from rapid degradation through a ubiquitin-proteasome-mediated process. We set out to test the hypothesis that chaperone proteins might be involved in targeting TPMT for degradation. As a first step, hsp90, hsp70 and the cochaperone hop were immunoprecipitated from a rabbit reticulocyte lysate (RRL) that included radioactively labelled *3A and wild-type TPMT. TPMT*3A was much more highly associated with all three chaperones than was the wild-type enzyme. The RRL was also used to confirm the accelerated degradation of *3A compared to wild-type TPMT. Treatment of RRL with the hsp90 inhibitor geldanamycin resulted in enhanced association of hsp90 with wild-type TPMT, an observation that correlated with accelerated ubiquitin-dependent degradation of wild-type TPMT. Geldanamycin treatment of COS-1 cells transfected with FLAG-tagged wild-type also resulted in a time and geldanamycin concentration-dependent decrease in TPMT activity and protein, which was compatible with results obtained in the RRL. These observations indicate that TPMT is a client protein for hsp90 and suggest that chaperone proteins, especially hsp90, are involved in targeting both TPMT*3A and, in the presence of geldanamycin, the wild-type allozyme for degradation. Therefore, chaperone proteins play an important mechanistic role in this clinically significant example of pharmacogenetic variation in drug metabolism.
- 1 January 2003
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 8 (2) , 108-13
p23, a simple protein with complex activities
P23 is a small but important cochaperone for the Hsp90 chaperoning pathway. It appears to facilitate the adenosine triphosphate-driven cycle of Hsp90 binding to client proteins. It enters at a late stage of the cycle and enhances the maturation of client proteins. Although this role of p23 is fairly well established, recent studies suggest that it may have additional functions in the cell that merit further exploration.
- 1 January 2003
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 8 (2) , 108-13
p23, a simple protein with complex activities
P23 is a small but important cochaperone for the Hsp90 chaperoning pathway. It appears to facilitate the adenosine triphosphate-driven cycle of Hsp90 binding to client proteins. It enters at a late stage of the cycle and enhances the maturation of client proteins. Although this role of p23 is fairly well established, recent studies suggest that it may have additional functions in the cell that merit further exploration.
- Open Access
- 1 October 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (41) , 38294-38304
The Assembly and Intermolecular Properties of the hsp70-Hop-hsp90 Molecular Chaperone Complex
- 1 October 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (41) , 38294-38304
Open AccessThe Assembly and Intermolecular Properties of the hsp70-Hop-hsp90 Molecular Chaperone Complex
- Open Access
- 24 October 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (23) , 12524-12529
Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90
Heat shock protein (hsp)90 functions in a complex chaperoning pathway where its activity is modulated by ATP and by interaction with several co-chaperones. One co-chaperone, p23, binds selectively to the ATP-bound state of hsp90. However, the isolated ATP-binding domain of hsp90 does not bind p23. In an effort to identify the p23-binding domain, we have constructed a series of hsp90 deletion mutants fused with glutathione- S -transferase (GST). Full-length GST-hsp90 is able to bind p23, and also, to chaperone assembly of progesterone receptor complexes. Truncations from the C terminus of GST-hsp90 reveal a C-terminal boundary for the p23-binding domain at approximately residue 490. This fragment contains, in order, the ATP-binding domain, a highly charged region, and 203 residues beyond the charged region. p23 binding is unaffected by deletion of the charged region, indicating that two noncontiguous regions of hsp90 are involved in p23 binding. These regions are only effective when hsp90 is in a dimeric state as shown by loss of p23 binding upon removal of GST or as shown by use of FK506-binding protein12-hsp90 constructs that form dimers and bind p23 only in the presence of a bivalent drug. Thus, p23 binding requires an hsp90 dimer with close proximity between N-terminal regions of hsp90 and a conformation specified by ATP.
- 24 October 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (23) , 12524-12529
Open AccessDimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90
Heat shock protein (hsp)90 functions in a complex chaperoning pathway where its activity is modulated by ATP and by interaction with several co-chaperones. One co-chaperone, p23, binds selectively to the ATP-bound state of hsp90. However, the isolated ATP-binding domain of hsp90 does not bind p23. In an effort to identify the p23-binding domain, we have constructed a series of hsp90 deletion mutants fused with glutathione- S -transferase (GST). Full-length GST-hsp90 is able to bind p23, and also, to chaperone assembly of progesterone receptor complexes. Truncations from the C terminus of GST-hsp90 reveal a C-terminal boundary for the p23-binding domain at approximately residue 490. This fragment contains, in order, the ATP-binding domain, a highly charged region, and 203 residues beyond the charged region. p23 binding is unaffected by deletion of the charged region, indicating that two noncontiguous regions of hsp90 are involved in p23 binding. These regions are only effective when hsp90 is in a dimeric state as shown by loss of p23 binding upon removal of GST or as shown by use of FK506-binding protein12-hsp90 constructs that form dimers and bind p23 only in the presence of a bivalent drug. Thus, p23 binding requires an hsp90 dimer with close proximity between N-terminal regions of hsp90 and a conformation specified by ATP.